Veterinary research communications
December 1, 2024
Luis Alberto Henríquez-Hernández, Ignacio García-Serrano, Domingo J Quintana-Hernández et al.
4 citations
Anxiety affects 14-20% of dogs. Pharmacological treatments often fail. Psychedelics have shown to be useful for anxiety and depression in humans, but their veterinary use remains unexplored. We aimed to determine the effects of low-dose 1-cyclopropionyl-d-lysergic acid diethylamide (1cp-LSD) administered in a single dose to a dog, to observe the effect and establish the safety of the substance....
Current Topics in Behavioral Neurosciences
October 23, 2024
Grace Viljoen, Felix Betzler
5 citations
There is a large and rapidly growing body of literature investigating the therapeutic effects of classic psychedelics in affective and anxiety disorders, but very few studies have examined the inverse of this, that is, the potential for psychedelics to inflict anxiety and affective symptoms. A systematic literature search was performed and 39 papers were included in the final review to...
The British journal of psychiatry : the journal of mental science
September 1, 2024
Friederike Holze, Peter Gasser, Felix Müller et al.
32 citations
Anxiety disorders are a major public health burden with limited treatment options. We investigated the long-term safety and efficacy of lysergic acid diethylamide (LSD)-assisted therapy in patients with anxiety with or without life-threatening illness. This study was an a priori-planned long-term follow-up of an investigator-initiated, two-centre trial that used a double-blind,...
Journal of Pakistan Psychiatric Society
June 30, 2024
Nauman Ashraf
1 citation
Psychedelics, substances known to alter perception, mood, and consciousness, have been used across various cultures for centuries, often in religious ceremonies to facilitate spiritual experiences. Lysergic acid diethylamide (LSD) was used clinically from the 1950s until its ban in 1967. Recently, there has been a resurgence of interest in psychedelics for treating mental health disorders such...
medRxiv
June 20, 2024
Dimy Fluyau, Vasanth Kattalai Kailasam, Neelambika Revadigar
preprint
Abstract Background Hallucinogens attract research as alternatives to the commonly used medications to treat major depressive and anxiety disorders. Aims Assess hallucinogens’ efficacy for managing depressive and anxiety symptoms and evaluate their safety profiles. Method In five databases, we searched for randomized controlled trials of hallucinogens targeting depressive and anxiety symptoms....
Psychiatric News
April 23, 2024
Terri D’arrigo
Back to table of contents Previous article Next article Med CheckFull AccessMedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and MoreTerri D'ArrigoTerri D'ArrigoPublished Online:23 Apr 2024https://doi.org/10.1176/appi.pn.2024.05.5.1Vanda Gets Yes for Iloperidone for Bipolar, No for InsomniaVanda Pharmaceuticals Inc. announced in April that the Food and Drug Administration...
Journal For International Medical Graduates
April 18, 2024
Sarosh Nawaz, Abdulaziz Mohammed Althwanay, B Esraa M. Aledani Mb Ch et al.
The impact of psychedelic treatment on patients suffering from psychiatric diseases like depression, anxiety, post-traumatic psychiatric disorder (PTSD), and existential distress related to cancer has become very intriguing to psychiatrists in the modern era. Serotonergic psychedelics include Lysergic acid diethylamide (LSD), psilocybin, mescaline, ayahuasca, and methylene-deoxy methamphetamine...
Scientific Reports
February 22, 2024
Ethan V Hagen, Melike Schalomon, Yanbo Zhang et al.
11 citations
The therapeutic use of lysergic acid diethylamide (LSD) has resurfaced in the last decade, prompting further scientific investigation into its effectiveness in many animal models. Zebrafish (Danio rerio) are a popular model organism in medical sciences and are used to examine the repeated administration of pharmacological compounds. Previous zebrafish research found acute LSD altered behaviour...
December 26, 2023
Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al.
preprint
Background: Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsychiatric conditions, including conditions that have not benefited from prior interventions. The latter half of the twentieth century marked a revolution in the treatment of depression, anxiety, and psychosis, exemplified by the...
Journal of Sociology Psychology & Religious Studies
November 6, 2023
Sarah Naher, Sarah Naher
1 citation
Mental illnesses pose social, economic, and health burdens worldwide. The increasing health burden and mental diseases pose the need for investigating other potential medications. The present review focuses on psychedelic medications. The Patient/Participant, Intervention, Outcomes, and Studies ([PICOS) protocol and the Preferred Reporting Items for Systematic Reviews (PRISMA) checklist guided...